Synchroneuron Inc.
Synchroneuron is a biopharmaceutical company developing therapies for tardive dyskinesia and other related movement disorders. Its lead candidate SNC-102, a sustained-release formulation of acamprosate calcium is being evaluated in phase 2 trials for tardive dyskinesia (TD) and Tourette syndrome (TS) and in phase 1 trials for combat-related posttraumatic stress disorder (cPTSD).
Industries
biotechnology
health-care
pharmaceutical
Nr. of Employees
small (1-50)
Synchroneuron Inc.
Patents
Acamprosate formulations, methods of using the same, and combinations comprising the same
US-10166207-B2
View DetailsAcamprosate formulations, methods of using the same, and combinations comprising the same
US-9427420-B2
View DetailsAcamprosate formulations, methods of using the same, and combinations comprising the same
US-9421179-B2
View DetailsAcamprosate formulations, methods of using the same, and combinations comprising the same
US-9421178-B2
View Details
Acamprosate formulations, methods of using the same, and combinations comprising the same
US-10166207-B2
View DetailsAcamprosate formulations, methods of using the same, and combinations comprising the same
US-9427420-B2
View DetailsAcamprosate formulations, methods of using the same, and combinations comprising the same
US-9421179-B2
View DetailsAcamprosate formulations, methods of using the same, and combinations comprising the same
US-9421178-B2
View Details